Safety and metabolism of long-term administration of NIAGEN (NR) in healthy overweight adults

Plain-language summary

Published 2019 in Scientific Reports, this work by Conze D and collaborators tackles a specific question within nr-focused NMN/NAD+ research.

Key findings reported by the authors

• NR 1g/day for 8 weeks well tolerated
• Statistically significant NAD+ elevation
• No clinically meaningful adverse events

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the strong end of the evidence spectrum. Strong-tier human placebo-controlled trial data carries the most weight in our editorial framework - treat findings as actionable signal, but always pair with at least one replication. Findings here are most directly relevant to nr decisions, with secondary relevance to safety and clinical-trial. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.